| Indication | Metastatic non-small cell lung cancer |
| Drug | XTX501 |
| Mechanism of Action | bispecific PD-1 / masked IL-2 |
| Company | Xilio Therapeutics, Inc. |
| Trial Phase | Phase 1/2 |
| NCT ID | NCT07688577 |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Oncology |
| Regulatory Agency | U.S. Food and Drug Administration (FDA) |
| Regulatory Action | IND clearance |
| Trial Initiation Timing (XTX501) | Second half of 2026 |
| Initial Data Reporting Timing (XTX501) | Second half of 2027 |
| Collaboration Partners | AbbVie Group Holdings Limited, Gilead Sciences, Inc. |
| Cash and Cash Equivalents (June 30, 2026) | $136.0 million |
| Net Loss (Q2 2026) | $6.4 million |
| Cash Runway Projection | Into the first quarter of 2028 |
| IND Submission Anticipation (TCE Programs) | Second half of 2027 |
| Target Antigens (TCE Programs) | CLDN18.2, PSMA+STEAP1 |
Xilio Therapeutics Receives FDA IND Clearance for XTX501
Xilio Therapeutics announced its second quarter 2026 financial results and pipeline advancements, highlighted by the FDA clearance of its Investigational New Drug (IND) application for XTX501, a bispecific PD-1 / masked IL-2. The company plans to initiate a Phase 1/2 clinical trial for XTX501 in patients with metastatic non-small cell lung cancer and other advanced solid tumors in the second half of 2026. Financially, Xilio reported $136.0 million in cash and cash equivalents as of June 30, 2026, and a net loss of $6.4 million for the quarter, projecting a cash runway into the first quarter of 2028.
- Xilio Therapeutics secured FDA clearance for its IND application for XTX501, a novel bispecific PD-1 / masked IL-2. This enables the company to proceed with a Phase 1/2 clinical trial, with dosing expected to begin in the second half of 2026 for patients with metastatic non-small cell lung cancer and select advanced solid tumors. Initial Phase 1 data for metastatic NSCLC is anticipated in the second half of 2027.
- Xilio is actively progressing IND-enabling studies for two potential first-in-class masked T cell engager (TCE) programs. These include a TCE targeting CLDN18.2, expressed in gastrointestinal cancers, and a multi-specific TCE targeting PSMA and STEAP1, expressed in prostate cancer. The company aims to submit IND applications for these programs in the second half of 2027, leveraging its proprietary masking technology.
- Xilio Therapeutics reported a strong financial position with $136.0 million in cash and cash equivalents as of June 30, 2026, and a reduced net loss of $6.4 million for Q2 2026 compared to the prior year. The company anticipates its current cash resources will fund operations into the first quarter of 2028, supported by increased collaboration and license revenue from partnerships with AbbVie and Gilead.
The Persistent Challenges in Treating Advanced Solid Tumors
Metastatic non-small cell lung cancer (mNSCLC) remains one of the most difficult-to-treat malignancies, driven by profound molecular heterogeneity and a tumor microenvironment (TME) that is inherently immunosuppressive — factors that collectively sustain high mortality rates. Despite meaningful advances with immune checkpoint inhibitors (ICIs) and targeted therapies, critical gaps in efficacy, durability, and patient selection persist across treatment lines.
Low and variable ICI response rates: Although ICIs demonstrate a survival advantage over chemotherapy in both first- and second-line settings, the overall response rate remains approximately 20%, and a substantial proportion of patients experience disease progression within the first weeks of treatment. Resistance to immunotherapy and immune-related adverse events (irAEs) continue to represent major clinical obstacles.
Inevitable acquired resistance to targeted therapies: All patients receiving tyrosine kinase inhibitor (TKI) therapy ultimately develop acquired resistance through well-characterized mechanisms — including secondary mutations within the kinase domain, activation of bypass signaling pathways, or histological transformation such as small-cell lung cancer (SCLC) conversion. Acquired resistance to ICIs, including SCLC transformation, adds further complexity. Data on mechanisms underlying primary resistance and mixed responses remain notably limited.
CNS sanctuary site and blood-brain barrier penetration: Brain metastases complicate the clinical course of NSCLC in approximately 25–40% of cases, with the blood-brain barrier (BBB) functioning as a sanctuary site that limits drug exposure. This adversely impacts both quality of life and overall survival.
Biomarker inadequacy for ICI patient selection: PD-L1 expression has demonstrated inconsistent predictive value across trials, attributable to variability in assays, antibody platforms, and scoring thresholds — compounded by the inherent spatial and temporal heterogeneity of PD-L1 expression itself. PD-L1 alone is insufficient as a predictive biomarker, underscoring the urgent need for more robust, validated alternatives.
Frequently Asked Questions
References
- [1] Shalata W, Naamneh R et al.. Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Medical sciences (Basel, Switzerland). 2025 Sep 18. 40981198
- [2] Bar J, Ofek E et al.. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2019 Dec. 31683093
- [3] Chen F, Du H et al.. A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report. Medicine. 2023 Jan 20. 36701715
- [4] Porcu M, De Silva P et al.. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers. 2019 Mar 5. 30841554
- [5] Lai SY, Bhardwaj S et al.. Leptomeningeal Carcinomatosis: A Rare Complication of Metastatic Gastric Cancer. Cureus. 2023 Jan. 36843688
- [6] Cardona AF, Arrieta O et al.. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). Targeted oncology. 2017 Aug. 28620690
- [7] Proto C, Imbimbo M et al.. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Translational lung cancer research. 2016 Dec. 28149752
- [8] Greillier L, Tomasini P et al.. The clinical utility of tumor mutational burden in non-small cell lung cancer. Translational lung cancer research. 2018 Dec. 30505708
- [9] Yamada K, Azuma K et al.. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802). Anticancer research. 2016 Jun. 27272800
- [10] De Carlo E, Schiappacassi M et al.. Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. OncoTargets and therapy. 2018. 30573982
- [11] Zhou X, Zhou L et al.. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Oct 13. 37581611
- [12] Choudhary F, Safdar A et al.. Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer. Mini reviews in medicinal chemistry. 2026. 41169141
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
